Earnings per share amounted to $3.61, falling short of analysts’ expectations of $4.68 per share, according to Reuters. Revenue fell 29 percent to $5.1 billion.
The increase in costs also had a negative impact on the economy, operating costs almost doubled. The company spent 87 percent more on research and development than in the same period of the previous year. Among the products the company is working on is a possible vaccine against skin cancer.
This year, the company expects sales of the vaccine against covid-19 to be at least five billion USD (111.7 billion CZK). Last year they amounted to USD 18.4 billion (CZK 411 billion).
The covid-19 vaccine is the company’s main source of revenue, apart from grants and cooperation money. Thanks to this, Moderna earned a record profit of $18.5 billion (CZK 413.7 billion) for the entire year 2021. Compared to 2020, when the company reported a profit of “only” 803 million dollars (CZK 18 billion), this was an astronomical increase.
At the end of January, Pfizer said that this year it expects sales of the vaccine to drop to $13.5 billion (CZK 301.5 billion) from last year’s USD 37.8 billion (CZK 844.1 billion).
Moderna is suing Pfizer. He allegedly stole her covid vaccine technology
Europe
